infection control – Forte Medical

Forte Medical case study within Imperial College Innovation paper

30th July2023/in AMR, analysis, British business, business, diagnosis, diligence, Disruption, Enterprise, Evidence, export, FemTech, Finance, health, healthcare, infection control, innovation, Investment, Investors, medicine, MedTech, midstream, patient safety, pregnancy, research, sample, SME, specimen, testing, Uncategorized, urine, UTI /by Giovanna

Commissioned by Lord Sainsbury and authored by Professor James Moore and Yunus Kutlu, Imperial College has published a report on innovation adoption in the UK and wh

at prevents successful adoption of impactful innovation. Forte Medical features as the only case study and outlines issues with silo systems, a disconnect between procurement and fincance all topped off with vested interests from labs and leadership.

The Peezy Midstream case study outlines how adoption of preventative devices and practice are resisted, leading to missed opportunities for improved patient health, prompt diagnoses, prevention and huge cost savings across the patient pathway.

Read all about it here. – see Page 29 and Appendix 2

Imperial Business School: a MedTech to Market Journey

15th November2022/in AMR, analysis, antenatal, British business, business, diagnosis, Enterprise, Evidence, export, FemTech, Finance, health, healthcare, infection control, innovation, Investment, Investors, medicine, MedTech, midstream, patient safety, pregnancy, pregnant, research, sample, screening, Series A, SME, specimen, Uncategorized, urine, USA, UTI /by Giovanna

Giovanna’s annual talk to the Imperial Business School took place last week; here we share the presentation Deck. Had she known in 2002 what she knows now, it would have taken a third of the time to create three specimen collection products and a springboard to global reach. She and Dr Vincent Forte are beyond proud of what they have achieved. 202210_ForteMedical_HealthTech_Commercialisation_Journey

Antibiotics and urinary tract infections

Antibiotics, better tests, UTI: Guardian publishes Forte response

8th October2019/in AMR, analysis, antenatal, clinic, diagnosis, diligence, Disruption, health, healthcare, hospital, hygiene, infection control, innovation, medicine, MedTech, midstream, patient safety, pregnancy, pregnant, research, sample, screening, specimen, testing, Uncategorised, urine, UTI /by Forte Medical

A rise in persistent UTIs could be linked to antibiotic crackdown appeared in The Guardian on Saturday 5th October. As usual, no-one mentioned accurate basic specimen collection, which can lead to unwarranted specimen quality variation, failed analysis and less-than-targeted prescribing. Giovanna Forte had something to say. Click here to read her published letter.

Urine Is Liquid Gold When It Comes To Testing

17th January2019/in AMR, business, diagnosis, health & safety, infection control, innovation, midstream, specimen, testing, urine, UTI /by Forte Medical

Today’s Hippocratic Post features an overview on the importance of urine and the evidence supporting why our technology plays such a vital role in enabling right-first-time diagnosis and treatment.

ABHI Reception – The Role of HealthTech In Saving Lives

16th January2019/in British business, health & safety, healthcare, infection control, MedTech, specimen /by Forte Medical

We attended the ABHI Parliamentary Reception last night and CEO Giovanna Forte had the opportunity to speak with The Rt Hon Matt Hancock MP, Secretary of State for Health and Social Care about how Forte Medical’s technology could save the NHS £1.2bn in unnecessary retesting of urine samples, cancellation of operations, over prescribing of unnecessary antibiotics and much more.

The event, attended by over 200 delegates celebrated the critical role HealthTech plays in improving lives and supporting the NHS.

For more information, the ABHI document can be accessed here

IPC 2019 – We’re Exhibiting!

10th January2019/in British business, diagnosis, health & safety, infection control, innovation, patient safety, Uncategorised, urine /by Forte Medical

The future of preventative care, infection control, antimicrobial resistance and patient safety are routinely undermined by lazy attitudes towards urine collection, the most common diagnostic process. Despite mounting evidence to support the need for a respected protocol, incumbent methods are failing modern medicine, patient health and the work of diligent clinicians.

Want to know more about our mission – visit us on stand 23 – and see first hand our world-class diagnostic specimen collection technology; Peezy Midstream reduces false-positive dipped urines by almost 70% and specimen contamination to just 2%. Current contamination is 23.5%, leading to 1 in 4 failed urine specimens – that’s over 14m annually or 56,000 every day. The unique Peezy Midstream delivers diagnostic integrity leading to targeted treatment; it helps address growing problems of infection control, unnecessary broad-spectrum antibiotic prescribing, AMR, and failed treatment of conditions that can become chronic.

Attending the Greater Irvine Chamber’s 2018 Life Sciences

14th November2018/in British business, business, export, Finance, infection control, innovation, Investment, MedTech, SME, USA /by Forte Medical

Giovanna Forte, CEO was delighted to be one of 10 British executives to make their way to UC Irvine (UCI) for the Greater Irvine Chamber’s 2018 Life Science Showcase event.

In collaboration with UCI Applied Innovation, the Greater Irvine Chamber hosted UK owned life science companies to position Southern California and UCI as a strong global brand for innovation and entrepreneurship. Applied Innovation worked closely with the chamber to promote industry cluster growth in the region.

Click here to read more about the event

Mr Ased Ali – Making Urine Samples Trustworthy

6th November2018/in analysis, diagnosis, diligence, health, infection control, midstream, patient safety, sample, specimen, testing, urine /by Forte Medical

The latest issue of Urology News features an interesting and important conversation with Urological Consultant Mr Ased Ali about the importance of urine in diagnosis and subsequent treatment of UTIs. He refers to the patient-led initiative – the MUST Campaign – that is demanding Government introduce a protocol for the collection of urine specimens.

The article supports the work being undertaken – the petition can be signed here – and the article itself is on page 35 of the November/December issue.

Clinical research using the Peezy Midstream shows a 70% reduction in false positive dipped urines and mixed growth/contamination reduced from the national average of 22.5% to just 2%. Our contribution to making urine samples trustworthy

Peezy Midstream Case Study at NHS NIHR Conference 2018

12th October2018/in analysis, business, diagnosis, health, health & safety, healthcare, hospital, hygiene, infection control, midstream, patient safety, research, sample, specimen, testing /by Forte Medical

Back in March of this year, the NHS National Institute for Health Research contacted Forte Medical, asking for a case study demonstrating how their research has assisted the launch of Peezy Midstream.

A few months earlier the NIHR in conjunction with the West Midlands AHSN conducted a valuable Usability Study on our diagnostic device. Results were excellent and have assisted us with adoption training and reassurance to HCPs and patients alike that using Peezy Midstream is far, far easier than trying to deliver this elusive urine specimen any other way …

The case study presented by Giovanna Forte on 10th October 2018 was very well received and has already led to enquiries from Primary Care clinicians who can see the benefit of right-first-time diagnoses for UTI and other common conditions that can take up so much GP time when left untreated.

2018 NIHR Peezy Presentation

NIHR_PeezyMidstream-Case-Study

“If you come down with a UTI, seek treatment and get your urine tested.”

29th August2018/in AMR, diagnosis, infection control, midstream, specimen, urine, USA, UTI /by Forte Medical

This is the latest recommendation following publication of a Californian study about the rise of antibiotic-resistant bacteria. But right-first-time diagnosis and treatment is only possible if the urine sample is collected correctly in the first place.

In the UK, nearly 1 in 3 women will have a UTI by the time they are 24 and around 1 in 30 boys by the age of 16. Additionally – according to the Unplanned Admissions Committee the NHS spent £434 million in 2013/14 on treating 184,000 patients in unplanned admissions associated with a UTI.

Forte Medical case study within Imperial College Innovation paper

Imperial Business School: a MedTech to Market Journey

Antibiotics, better tests, UTI: Guardian publishes Forte response

Urine Is Liquid Gold When It Comes To Testing

ABHI Reception – The Role of HealthTech In Saving Lives

IPC 2019 – We’re Exhibiting!

Attending the Greater Irvine Chamber’s 2018 Life Sciences

Mr Ased Ali – Making Urine Samples Trustworthy

Peezy Midstream Case Study at NHS NIHR Conference 2018

“If you come down with a UTI, seek treatment and get your urine tested.”

WEB MAP

GET IN TOUCH

Forte Medical

SOCIAL MEDIA

Latest from Twitter